Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease

Table 4 Comparison of the parameter decrease degree in subgroups with weight loss of more and less than 5% from baseline to the end of treatment

Parameter	Weight loss > 5% (n = 54)	Weight loss ≤ 5% (n = 120)	P value
∆ALT, U/L	-21.1 (-45.0; -6.0)	-25.0 (-42.5; -6.0)	0.683
∆ALT, %	-46 (-63; -18)	-43 (-54; -23)	0.281
∆AST, U/L	-6.0 (-15.0; 1.6)	-5.0 (-18.0; 1.0)	0.673
∆AST, %	22 (-41; 0)	-17 (-42; 0)	0.446
∆GGT, U/L	-5.0 (-17.0; 0)	-8.0 (-22.5; 0)	0.492
∆GGT, %	-19 (-41; 0)	-32 (-50; 0)	0.354
∆TC, mmol/L	-0.10 (-0.66; 0.30)	-0.10 (-0.57; 0.2)	0.666
∆TG, mmol/L	-1.04 (-1.80; -0.23)	-0.70 (-1.33; -0.11)	0.079
∆LDL, mmol/L	-0.20 (-0.7; 0.2)	-0.14 (-0.58; 0.3)	0.401
FLI
Initially	88.3 ± 10.2	83.5 ± 10.3	0.002
After 6 mo	71.4 ± 19.6c	72.8 ± 16.7c	0.916
∆FLI	-14.6 (-21.8; -6.3)	-8.45 (-17.9; -2)	0.003

^cP < 0.001. ∆ is the difference in indicators after 6 mo and at baseline. The minus sign indicates a decrease in the parameter by the end of the study.